Samouilidou Elisabeth, Athanasiadou Virginia, Grapsa Eirini
Department of Biochemistry, "Alexandra" Hospital, Athens, Greece.
Renal Unit, "Aretaeio" Hospital, Athens, Greece.
Int J Nephrol. 2022 Mar 14;2022:3861092. doi: 10.1155/2022/3861092. eCollection 2022.
Endocan, previously called endothelial cell-specific molecule-1, is a soluble proteoglycan that is predominantly expressed in vascular endothelial cells of the lungs and kidneys. It is upregulated by proinflammatory cytokines and plays a critical role in inflammatory, proliferative, and neovascularization processes. The utility of endocan as a biomarker in a wide spectrum of diseases is being increasingly acknowledged. In this review, we summarize the current evidence concerning the role of endocan in kidney diseases, with emphasis on its prognostic and diagnostic value. It seems that the determination of plasma endocan levels may provide useful prognostic information in many types of renal failure such as chronic kidney disease, IgA nephropathy, and diabetic nephropathy. Endocan could additionally improve the early diagnostic evaluation of acute kidney disease, chronic renal allograft injury, and acute rejection after kidney transplantation, thus contributing to endothelial cell injury monitoring in a timely manner.
内皮糖蛋白，以前称为内皮细胞特异性分子-1，是一种可溶性蛋白聚糖，主要在肺和肾的血管内皮细胞中表达。它由促炎细胞因子上调，并在炎症、增殖和新血管形成过程中起关键作用。内皮糖蛋白作为一种生物标志物在多种疾病中的应用正日益得到认可。在本综述中，我们总结了关于内皮糖蛋白在肾脏疾病中作用的当前证据，重点是其预后和诊断价值。似乎血浆内皮糖蛋白水平的测定可能为许多类型的肾衰竭提供有用的预后信息，如慢性肾脏病、IgA肾病和糖尿病肾病。内皮糖蛋白还可以改善急性肾损伤、慢性肾移植损伤和肾移植后急性排斥反应的早期诊断评估，从而有助于及时监测内皮细胞损伤。
